|
Aug 30
|
J&J launches MatrixSternum fixation system for cardiac surgery in the US
|
|
Aug 29
|
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
|
|
Aug 29
|
Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
|
|
Aug 29
|
J&J submits touted autoimmune disease drug for FDA approval
|
|
Aug 29
|
Biocon Biologics signs agreement with Janssen to market Bmab 1200
|
|
Aug 29
|
The Zacks Analyst Blog Highlights Johnson & Johnson, Kenvue and Eli Lilly
|
|
Aug 28
|
Is Johnson & Johnson (JNJ) The Best Dividend Paying Stock To Buy According to Quant Hedge Fund AQR?
|
|
Aug 28
|
J&J's Rybrevant Receives EU Approval for Expanded Use in NSCLC
|
|
Aug 28
|
LifeNet launches newest bone allograft gel with Johnson & Johnson
|
|
Aug 28
|
Johnson & Johnson (JNJ): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
|
|
Aug 27
|
EC upgrades approval for J&J’s Rybrevant/chemotherapy combination in NSCLC
|
|
Aug 27
|
Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?
|
|
Aug 27
|
Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder
|
|
Aug 27
|
Biosense Webster completes enrolment for Omnypulse Platform trial
|
|
Aug 27
|
Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress
|
|
Aug 27
|
RA Capital-backed startup raises $100M; UCB sells China business
|
|
Aug 27
|
Meet Wall Street's Safest Dividend Stock: A Small-Cap Company Few Investors Know Exists
|
|
Aug 26
|
Johnson & Johnson Aims New Policy For Hospital Payments Under 340B Drug Discount Program Related To Its Flagship Blood Thinner And Arthritis Drugs
|
|
Aug 26
|
J&J (JNJ) Gets EU Approval for Bladder Cancer Drug Balversa
|
|
Jul 29
|
Big Pharma Rallies and Moves Past Obesity
|